Advertisement
Conference Call and Webcast Information
To access the live call, please dial 800-561-2693 (domestic) or617-614-3523 (international) 10 minutes prior to the start time and use thepasscode 36883961. A replay of the call will be available, in webcast andpodcast formats, at approximately 6:00 p.m. PST on December 7, 2008 throughDecember 14, 2008. To access the replay, please dial 888-286-8010 (domestic)or 617-801-6888 (international) and use the passcode 47095093. The conferencecall will also be webcast live and can be accessed from Rigel's website athttp://www.rigel.com. Please connect to Rigel's website several minutes priorto the start of the live webcast to ensure adequate time for any softwaredownloads that may be necessary.
Advertisement
In addition, Rigel will be participating in a plenary session during the50th Annual American Society of Hematology (ASH) Meeting in San Francisco,California from December 6-9, 2008.
ASH Presentation Details
Plenary session: Sunday, December 7, 2008 - 2:40 p.m. PST
Title: 3 - Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, IsWell-Tolerated and Has Significant Clinical Activity in Diffuse Large B-CellLymphoma (DLBCL) and Chronic Lymphoctytic Leukemia (SLL/CLL)
Location: Halls B and C (Moscone Center)
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers anddevelops novel, small-molecule drugs for the treatment ofinflammatory/autoimmune diseases and cancer, as well as viral and metabolicdiseases. Our pioneering research focuses on intracellular signaling pathwaysand related targets that are critical to disease mechanisms. Rigel'sproductivity has resulted in strategic collaborations with largepharmaceutical partners to develop and market our product candidates. Rigelhas product development programs in inflammatory/autoimmune diseases such asrheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.Contact: Raul Rodriguez Phone: 650.624.1302 Email: [email protected] Media Contact: Susan C. Rogers, Alchemy Consulting, Inc. Phone: 650.430.3777 Email: [email protected]
SOURCE Rigel Pharmaceuticals, Inc.
